Reference
Hernandez AO, et al. Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review. 46th European Society for Medical Oncology Congress : abstr. 1832P, 16 Sep 2021. Available from: URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/cardiotoxicity-of-the-her2-dimerisation-inhibitor-pertuzumab-in-patients-with-breast-cancer-her2-a-systematic-review
Rights and permissions
About this article
Cite this article
Pertuzumab increases risk of cardiac events in breast cancer patients. Reactions Weekly 1883, 11 (2021). https://doi.org/10.1007/s40278-021-05966-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-05966-9